OSE Immunotherapeutics General Meeting Rescheduled
OSE Immunotherapeutics, a pioneering biotech firm, has recently announced the adjournment of its mixed General Meeting, which was originally set for June 25, 2025. This decision was taken to clarify the situation regarding the meeting organization.
Details of the Adjournment
The company made the announcement following a concerted declaration published on the Autorité des Marchés Financiers website on June 3, 2025. As per earlier communication, the management sought an extension from the President of the Nantes Commercial Court for the legal timeline to conduct the General Meeting. This request was approved, granting an extension until September 30, 2025.
Corrective Measures and Future Plans
In light of the extension granted by the judicial authority, the Board of Directors of OSE Immunotherapeutics is fully aware of the implications of this decision. It has committed itself to organizing the General Meeting within the newly established parameters to assure both compliance and transparency.
During this interim period, the company pledges to rigorously check all necessary documents and ensure that shareholders can access comprehensive information before the next meeting date. Proxy forms previously submitted are now null and void, and fresh details about the new agenda and voting protocols will be shared shortly.
Communication from the Board
Chairperson Didier Hoch expressed his gratitude to the shareholders while addressing this postponement, stating, "We understand the importance of this meeting and are dedicated to keeping you fully informed. It is our collective responsibility as shareholders to approach this meeting with the necessary insights to make informed decisions regarding the future of our company. OSE Immunotherapeutics remains a vibrant and innovative entity with ongoing clinical trials and research programs, and it is essential for us to maintain this momentum in our service to patients. We are committed to transparency and constructive dialogue as we prepare for the rescheduled General Meeting."
Commitment to Transparency
OSE Immunotherapeutics emphasizes its ongoing dedication to transparent governance and effective communication with its shareholders. The company will actively keep all stakeholders updated on the developments related to the General Meeting as they unfold. This engagement ensures that everyone involved can make informed decisions based on the most accurate and up-to-date information available.
About OSE Immunotherapeutics
OSE Immunotherapeutics is at the forefront of biotech, focusing on the development of pioneering therapies within the fields of immuno-oncology and immuno-inflammation. The company aims to address critical patient needs that are currently unmet through innovative research and strategic collaborations with renowned academic and biopharmaceutical partners. With a base of operations in Nantes and Paris, OSE Immunotherapeutics is a listed entity on the Euronext exchange.
Contact Information
Fiona Olivier
Email: fiona.olivier@ose-immuno.com
Sylvie Détry
Email: sylvie.detry@ose-immuno.com
Frequently Asked Questions
What is the reason for the adjournment of the General Meeting?
The General Meeting was adjourned to clarify certain organizational aspects and ensure compliance with regulations.
When will the new General Meeting date be announced?
The company is expected to communicate the new date for the General Meeting soon, following full preparations.
What changes are affecting proxy forms already submitted?
All previously submitted proxy forms have become void due to the rescheduling of the General Meeting.
How will OSE Immunotherapeutics ensure transparency moving forward?
The company has committed to keeping shareholders informed of all developments and ensuring access to relevant information.
What is OSE Immunotherapeutics' core focus?
OSE Immunotherapeutics is dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation to meet urgent medical needs.
